Optimal induction of upper respiratory tract immunity to reovirus 1/L by combined upper and lower respiratory tract inoculation

Vaccine

Volumn 17, Issue 11-12, 1999, Pages 1404-1415

  Hodson Thompson, Amy ^a   McRoberts, John G ^a   Crowe, Sherry R ^a   London, Lucille ^a   London, Steven D ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Antibody; Reovirus; Respiratory tract

Indexed keywords

REOVIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; INOCULATION; INTRANASAL DRUG ADMINISTRATION; LYMPHOID TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REOVIRUS; RESPIRATORY TRACT INFECTION; VACCINATION; VIRUS INFECTION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; BRONCHOALVEOLAR LAVAGE FLUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNITY, MUCOSAL; LYMPHOCYTE COUNT; MICE; MICE, INBRED STRAINS; NASAL LAVAGE FLUID; NASAL MUCOSA; ORTHOREOVIRUS; REOVIRIDAE INFECTIONS; RESPIRATORY SYSTEM; RESPIRATORY TRACT INFECTIONS; VIRAL VACCINES;

EID: 0345251980     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00382-X     Document Type: Article

References (31)

1. Kuper C.F., Koornstra P.J., Hameleers D.M., Biewenga J., Spit B.J., Duijvestijn A.M., van Breda Vriesman P.J., Sminia T. The role of nasopharyngeal lymphoid tissue. Immunol Today. 13:1992;219-224.
2. Asanuma H., Thompson A.H., Iwasaki T., Sato Y., Inaba Y., Aizawa C., Kurata T., Tamura S.-I. Isolation and characterization of mouse nasal-associated lymphoid tissue. J Immunol Methods. 202:1997;123-131.
3. Asakura K., Saito H., Hata M., Kataura A. Antigen specific immunoglobulin production by NALT lymphocytes in rats. Acta Otolaryngol Suppl (Stockholm). 523:1996;80-83.
4. Wu H.Y., Nikolova E.B., Beagley K.W., Russell M.W. Induction of antibody-secreting cells and T-helper and memory cells in murine nasal lymphoid tissue. Immunology. 88:1996;93-100.
5. Wu H.Y., Russell M.W. Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system. Immunol Res. 16:1997;187-201.
6. Heritage P.L., Underdown B.J., Arsenault A.L., Snider D.P., McDermott M.R. Comparison of murine nasal-associated lymphoid tissue and Peyerís Patches. Am J Respir Crit Care Med. 156:1997;1256-1262.
7. Tamura S.-I., Iwasaki T., Thompson A.H., Asanuma H., Chen Z., Suzuki Y., Aizawa C., Kurata T. Antibody-secreting cells in the nasal-associated lymphoid tissue during primary influenza virus infection. J Gen Virol. 79:1998;291-299.
8. Liew F.Y., Russell S.M., Appleyard G., Brand C.M., Beale J. Cross-protection in mice infected with influenza A virus by the repiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T-cell reactivity. Eur J Immunol. 14:1984;350-356.
9. Renegar K.B., Small P.A. Jr. Immunoglobulin A mediation of murine nasal anti-influenza virus immunity. J Virol. 65:1991;2146-2148.
10. Renegar K.B., Small P.A. Jr. Passive transfer of local immunity to influenza virus infection by IgA antibody. J Immunol. 146:1991;1972-1978.
11. Kris R.M., Yetter R.A., Cogliano R., Ramphal R., Small P.A. Passive serum antibody causes temporary recovery from influenza virus infection of the nose, trachea and lung of nude mice. Immunology. 63:1988;349-353.
12. Palladino G., Mozdzanowska K., Washko G., Gerhard W. Virus-neutralizaing antibodies of Immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. J Virol. 69:1995;2075-2081.
13. Veggeberg S. Trial of nasal influenza vaccine expands. Mol Med Today. 3:1997;468.
14. Owens S.L., Osebold J.W., Zee Y.C. Dynamics of B-lymphocytes in the lungs of mice exposed to aerosolized influenza virus. Infect Immun. 33:1981;231-238.
15. Jones P.D., Ada G.L. Influenza virus-specific antibody-secreting cells in the murine lung during primary influenza virus infection. J Virol. 60:1986;614-619.
16. Bice D E., Gray R.H., Evans M.J., Muggenburg B.A. Identification of plasma cells in lung alveoli and interstitial tissues after localized lung immunization. J Leukocyte Biol. 41:1987;1-7.
17. Bellum S.C., Dove D., Harley R.A., Greene W.B., Judson M.A., London L., London S.D. Respiratory reovirus 1/L induction of intraluminal fibrosis. A model for the study of bronchiolitis obliterans organizing pneumonia. Am J Pathol. 150:1997;2243-2254.
18. Bellum S.C., Hamamdzic D., Thompson A.H., Harley R.A., London S.D., London L. Experimental reovirus serotype 1/strain Lang infectin of the lung: a model for the study of the lung in the context of mucosal immunity. Lab Invest. 74:1996;221-231.
19. Thompson A.H., London L., Bellum S.C., Hamamdzic D., Harley R.A., London S.D. Respiratory-mucosal lymphocyte populations induced by reovirus serotype 1 infection. Cell Immunol. 169:1996;278-287.
20. London SD. Reovirus-induced perturbations of mucosal T and B lymphocyte population. Dissertation, University of Pennsylvania, 1987.
21. Rubin D.H., Kornstein M.J., Anderson A.O. Reovirus serotype 1 intestinal infection: a novel replicative cycle with ileal disease. J Virol. 53:1985;391-398.
22. Baumgarth N., Brown L., Jackson D., Kelso A. Novel features of the respiratory tract T-cell response to influenza virus infection: lung T-cells increase expression of gamma interferon mRNA in vivo and maintain high levels of mRNA expression for interleukin-5 (IL-5) and IL-10. J Virol. 68:1994;7575-7581.
23. Czerkinsky C.C., Nilsson L., Nygren H., Ouchterlony O., Tarkowski A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods. 65:1983;109-121.
24. Lycke N. A sensitive method for the detection of specific antibody production in different isotypes from single lamina propria plasma cells. Scand J Immunol. 24:1986;393-403.
25. Fazekas G., Rosenwirth B., Dukor P., Gergely J., Rajnavolgyi E. IgG isotype distribution of local and systemic immune responses induced by influenza virus infection. Eur J Immunol. 24:1994;3063-3067.
26. Balkovic E.S., Six H.R. Pulmonary and serum isotypic antibody responses of mice to live and inactivated influenza virus. Am Rev Respir Dis. 134:1986;6-11.
27. Murphy B.R., Clements M.L. The systemic and mucosal immune response of humans to influenza A virus. Curr Top Microbiol Immunol. 146:1989;107-115.
28. King J.C., Lagos R., Bernstein D.I., Piedra P.A., Kotloff K., Bryant M., Cho I., Belshe R.B. Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops of spray to healthy children. J Infect Dis. 177:1998;1394-1397.
29. Belshe R.B., Mendelman P.M., Treanor J., King J., Bruber W.C., Piedra P., Bernstein D.I., Hayden F.G., Kotloff K., Zangwill K., Iacuzio D., Wolff M. The efficacy of live attenuated, cold-adapted trivalent, intranasal influenza virus vaccine in children. N Engl J Med. 338:1998;1405-1412.
30. Whitehead S.S., Juhasz K., Firestone C.Y., Collins P.L., Murphy B.R. Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees. J Virol. 72:1998;4467-4471.
31. Skiadopoulos M.H., Durbin A.P., Tatem J.M., Wu S.L., Paschalis M., Tao T., Collins P.L., Murphy B.R. Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes. J Virol. 72:1998;1762-1768.